Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 25,416Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Genvoya

02 7Prezista/Prezcobix/Rezolsta/Symtuza

03 3Revenue share - Symtuza

04 10Stribild

05 4Symtuza

PharmaCompass

01

arrow
ESCRS
Not Confirmed

02

arrow
ESCRS
Not Confirmed

03

arrow
ESCRS
Not Confirmed

04

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
ESCRS
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
ESCRS
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

05

arrow
ESCRS
Not Confirmed

06

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
ESCRS
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
ESCRS
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,083

2020 Revenue in Millions : 2,184

Growth (%) : -5

blank

07

arrow
ESCRS
Not Confirmed

08

arrow
ESCRS
Not Confirmed

09

arrow
ESCRS
Not Confirmed

10

Brand Name : Revenue share - Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
ESCRS
Not Confirmed

Brand Name : Revenue share - Symtuza

arrow
ESCRS
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 530

2021 Revenue in Millions : 531

Growth (%) : 0

blank